Form D · Biotechnology
ECM Therapeutics, Inc.
Warrendale, PA · CIK 0001743104
Offering snapshot reported Oct 10, 2025 · SEC filing
- Reported sold
- $35.2M Offering amount: $40M
- Investors reported
- 190 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 28, 2018 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$26,100,000 → $35,219,000
- Reported investors138 → 190
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 10, 2025 | Amendment | $35,219,000 | $9,119,000vs May 30, 2024 | 190 | SEC filing |
| May 30, 2024 | Amendment | $26,100,000 | $5,055,994vs Jun 9, 2023 | 138 | SEC filing |
| Jun 9, 2023 | Amendment | $21,044,006 | $5,120,000vs Sep 14, 2022 | 182 | SEC filing |
| Sep 14, 2022 | Amendment | $15,924,006 | $9,424,006vs Sep 18, 2019 | 147 | SEC filing |
| Jul 30, 2021 | Amendment | $10,091,006 | No comparison | Not reported | SEC filing |
| Sep 18, 2019 | Amendment | $6,500,000 | $4,056,500vs Jun 18, 2019 | 73 | SEC filing |
| Jun 18, 2019 | Amendment | $2,443,500 | $1,524,500vs Jun 8, 2018 | 31 | SEC filing |
| Jun 8, 2018 | Initial | $919,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-314165
Source: Form D, filed Oct 10, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen Badylak | Director, Executive |
| Katie Collins | Director, Executive |
| Jenna Dziki | Executive |
| Paul F. Fagan | Director, Executive |
| George Hussey | Executive |
| Lindsey Saldin | Executive |
| Christine Sheehy | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
118 Marshall Drive
Warrendale, PA, 15086
Warrendale, PA, 15086